Latest Conference Articles

October 8th 2022, 10:00am

PER® Precision Medicine Symposium: An Illustrated Tumor Board

John Lindsay Marshall, MD, discusses past, present, and future developments in molecular testing, as well as the unique offerings of tissue and blood tests and the ways in which these precise approaches will ultimately make cancer diagnosis and treatment more efficient and effective.

October 6th 2022, 4:00pm

Ivosidenib plus venetoclax with or without azacitidine showed an expected and tolerable safety profile with durable responses and a prolonged survival rate across acute myeloid leukemia disease groups.

October 5th 2022, 1:00pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Oral decitabine plus cedazuridine added to oral venetoclax demonstrated promising overall response rates in patients with acute myeloid leukemia who received the combination as a first-line treatment or after relapsing on prior therapies.

October 3rd 2022, 6:08pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Loncastuximab tesirine-lpyl combined with rituximab demonstrated encouraging antitumor activity and a feasible safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma.

October 3rd 2022, 5:00pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Momelotinib induced superior 24-week overall survival rates compared with danazol in thrombocytopenic, symptomatic, and anemic patients with myelofibrosis.

October 1st 2022, 10:00am

Society of Hematologic Oncology Annual Meeting (SOHO)

Belantamab mafodotin plus lenalidomide and dexamethasone showed durable responses in patients with relapsed/refractory multiple myeloma.

September 30th 2022, 2:00pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Treatment with rusfertide generated sustained hematocrit control at levels below 45% in patients with polycythemia vera, leading to a reduced need for repeated phlebotomy and eliminating this need in some patients, according to findings from 2 phase 2 clinical trials.

September 29th 2022, 8:55pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Ivosidenib plus azacitidine displayed favorable event-free survival, overall survival, and clinical responses compared with placebo plus azacitidine in patients with newly diagnosed, IDH1-mutated acute myeloid leukemia, according to findings from the phase 3 AGILE study.

September 21st 2022, 6:45pm

ESMO Congress

Alpelisib decreased the need for surgery and led to improvements in performance status and disease-related signs and symptoms in pediatric patients with PIK3CA-related overgrowth spectrum disease who received treatment with the PI3K inhibitor under compassionate use.

September 13th 2022, 7:17pm

ESMO Congress

The decline of prostate-specific antigen following treatment with lutetium Lu 177 vipivotide tetraxetan plus standard of care was linked with prolonged radiographic progression-free survival and overall survival in patients with progressive prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer.

September 13th 2022, 12:28am

ESMO Congress

The combination of lenvatinib and pembrolizumab was found to induce high response rates, including long-lasting remissions, and have acceptable safety in patients with metastasized anaplastic thyroid carcinoma and poorly differentiated thyroid carcinoma.

September 12th 2022, 7:38pm

OncLive News Network: On Location at ESMO 2022

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

September 12th 2022, 7:20pm

ESMO Congress

GSK3326595, a PRMT5 inhibitor, displayed modest efficacy and safety signals that were consistent with those that were previously reported with the agent among patients with advanced solid tumors.

September 12th 2022, 7:19pm

ESMO Congress

Adagrasib monotherapy and in combination with cetuximab generated encouraging responses in patients with advanced colorectal cancer harboring KRAS G12C mutations.

September 12th 2022, 7:16pm

ESMO Congress

Ribociclib plus endocrine therapy elicited statistically significant progression-free survival and overall survival benefits vs placebo plus endocrine therapy in patients with hormone receptor–positive/HER2-negative advanced breast cancer with visceral metastases, including those with liver metastases and multiple metastatic sites.

September 12th 2022, 6:30pm

ESMO Congress

An analysis of patient-reported outcomes from the phase 2 KEYNOTE-522 trial demonstrated that pembrolizumab was not associated with effects on health-related quality of life in patients with triple-negative breast cancer.

September 12th 2022, 5:53pm

ESMO Congress

Paul A. DiSilvestro, MD, discusses the 7-year follow up data of maintenance olaparib in advanced ovarian cancer.

September 12th 2022, 5:49pm

ESMO Congress

John H. Strickler, MD, discusses the results of tucatinib monotherapy in HER2-positive colorectal cancer.

September 12th 2022, 4:54pm

ESMO Congress

Results from a retrospective analysis presented during the 2022 ESMO Congress indicated that circulating tumor DNA could potentially be leveraged as a prognostic factor and a tumor-specific biomarker for diffuse large B-cell lymphoma in China.

September 12th 2022, 4:50pm

ESMO Congress

The combination of orelabrutinib and R-CHOP elicited a favorable overall response rate and progression-free response rate in patients with previously untreated non–germinal center B-cell–like diffuse large B-cell lymphoma (DLBCL) with extranodal disease.